特异性免疫治疗小儿过敏性哮喘的临床疗效
|
摘要
目的探讨特异性免疫治疗小儿过敏性哮喘的临床疗效。方法选取2016年1月～2017年6月在我院诊断治疗的过敏性哮喘患儿50例为研究对象,随机分为研究组与对照组各25例。两组均给予解痉平喘等常规治疗,研究组在常规治疗基础上给予变应原疫苗行皮下免疫治疗。比较两组治疗后生活质量、PEF(呼吸流量峰值,peak expiratory flow)变异率;比较两组临床疗效。结果研究组显效率显著高于对照组,总有效率显著高于对照组,差异有统计学意义(P <0.05)。治疗6个月后,两组PEF变异率较和治疗前显著下降,差异有统计学意义(P <0.05);治疗后,研究组PEF变异率显著低于对照组,差异有统计学意义(P<0.05)。治疗后两组生活质量均有显著改善,与治疗前比较差异有统计学意义(P <0.05);治疗后,研究组生活质量评分显著高于对照组,差异有统计学意义(P <0.05)。结论小儿过敏性哮喘在采用特异性免疫治疗能够显著提高临床疗效,减少复发次数,改善肺功能。
Objective To explore the clinical curative effect of specific immunotherapy for children with allergic asthma.Methods 50 children who were diagnosed as allergic asthma and treated in our hospital from January 2016 to June 2017 were selected as research objects.They were randomly divided into the study group and the control group,with 25 cases in each group.Both groups were given routine treatment such as spasmolysis and asthma relief while the study group was given subcutaneous immunotherapy with allergen vaccine on the basis of routine treatment.The quality of life and peak expiratory flow(PEF)variation rate after treatment were compared between the two groups.The clinical curative effects of two groups were compared.Results The obvious effective rate and total effective rate of the study group were significantly higher than those of the control group(P < 0.05).After 6 months of treatment,the PEF variation rate of the two groups decreased significantly compared with that before treatment,and difference was statistically significant(P < 0.05).After treatment,the PEF variation rate in the study group was significantly lower than that in the control group,and difference was statistically significant(P < 0.05).The quality of life of both groups was significantly improved after treatment,and the difference was statistically significant compared with that before treatment(P < 0.05).After treatment,the quality of life in the study group was significantly higher than that in the control group,and difference was statistically significant(P< 0.05).Conclusion Specific immunotherapy for children with allergic asthma can significantly improve the clinical curative effect,reduce the frequency of recurrences and improve lung function.
Objective To explore the clinical curative effect of specific immunotherapy for children with allergic asthma.Methods 50 children who were diagnosed as allergic asthma and treated in our hospital from January 2016 to June 2017 were selected as research objects.They were randomly divided into the study group and the control group,with 25 cases in each group.Both groups were given routine treatment such as spasmolysis and asthma relief while the study group was given subcutaneous immunotherapy with allergen vaccine on the basis of routine treatment.The quality of life and peak expiratory flow(PEF)variation rate after treatment were compared between the two groups.The clinical curative effects of two groups were compared.Results The obvious effective rate and total effective rate of the study group were significantly higher than those of the control group(P < 0.05).After 6 months of treatment,the PEF variation rate of the two groups decreased significantly compared with that before treatment,and difference was statistically significant(P < 0.05).After treatment,the PEF variation rate in the study group was significantly lower than that in the control group,and difference was statistically significant(P < 0.05).The quality of life of both groups was significantly improved after treatment,and the difference was statistically significant compared with that before treatment(P < 0.05).After treatment,the quality of life in the study group was significantly higher than that in the control group,and difference was statistically significant(P< 0.05).Conclusion Specific immunotherapy for children with allergic asthma can significantly improve the clinical curative effect,reduce the frequency of recurrences and improve lung function.
引文
[1]陈实,王灵,廖锋,等.舌下含服粉尘螨滴剂治疗学龄前与学龄期儿童过敏性哮喘伴变应性鼻炎的疗效评估[J].中华儿科杂志,2013,51(11):831-835.
[2]魏庆,农光民,蒋敏,等.南宁市城区0~14岁儿童哮喘流行病学调查[J].中华哮喘杂志(电子版),2013,7(2):80-83.
[3]陈国华,刘婧,付承,等.粉尘螨滴剂治疗尘螨过敏性支气管哮喘疗效观察[J].中外医学研究,2014,12(23):105-107.
[4]中华医学会儿科学分会呼吸学组《中华儿科杂志》编辑委员会.儿童支气管哮喘诊断与防治指南[J].中华儿科杂志,2008,46(10):745-753.
[5]Juniper EF,Guyatt GH,Cox FM,et al.Development and validation of the Mini Asthma Quality of Life Questionnaire[J].Eur Respir J,1999,14(1):32-38.
[6]王卫平.儿科学[M].北京:人民卫生出版社,2013:267.
[7]向莉,申昆玲.儿童常见过敏性疾病诊疗概述[J].中国医学前沿杂志(电子版),2013,5(8):1-5.
[8]黄腾,叶敏如,许尤佳.中医药联合标准化特异性免疫治疗儿童支气管哮喘50例临床观察[J].中国中西医结合杂志,2013,33(9):1284-1286.
[9]陈捷,吴敏,曾丽娜.小儿过敏性哮喘的特异性免疫治疗[J].中国现代医生,2013,51(18):29-30.
[10]韦欢,欧维琳,朱春江,等.舌下特异性免疫治疗前后哮喘患儿过敏原及血清总IgE的变化[J].中国医药导报,2012,9(24):8-10.
[11]孙立英,郭胤仕,王怡玮,等.舌下特异性免疫治疗对过敏性哮喘的临床疗效分析[J].临床肺科杂志,2011,16(6):852-853.
[12]郝冀,李晓辕,刘红梅,等.舌下含服尘螨滴剂治疗老年过敏性哮喘患者53例[J].中国老年学杂志,2012,32(14):3066-3067.
[13]曹开梅.小儿过敏性哮喘的特异性免疫治疗[J].中国卫生标准管理,2015,6(19):23-24.
[14]李羚,惠郁,钱俊,等.螨过敏性哮喘患儿标准化特异性免疫治疗3年的有效性观察[J].中国当代儿科杂志,2013,15(5):368-371.
[15]严飞飞,何晓娜,贾圆圆.小青龙方加减联合特异性免疫治疗小儿过敏性哮喘的疗效及其对肺功能的影响[J].亚太传统医药,2018,14(3):181-182.
[2]魏庆,农光民,蒋敏,等.南宁市城区0~14岁儿童哮喘流行病学调查[J].中华哮喘杂志(电子版),2013,7(2):80-83.
[3]陈国华,刘婧,付承,等.粉尘螨滴剂治疗尘螨过敏性支气管哮喘疗效观察[J].中外医学研究,2014,12(23):105-107.
[4]中华医学会儿科学分会呼吸学组《中华儿科杂志》编辑委员会.儿童支气管哮喘诊断与防治指南[J].中华儿科杂志,2008,46(10):745-753.
[5]Juniper EF,Guyatt GH,Cox FM,et al.Development and validation of the Mini Asthma Quality of Life Questionnaire[J].Eur Respir J,1999,14(1):32-38.
[6]王卫平.儿科学[M].北京:人民卫生出版社,2013:267.
[7]向莉,申昆玲.儿童常见过敏性疾病诊疗概述[J].中国医学前沿杂志(电子版),2013,5(8):1-5.
[8]黄腾,叶敏如,许尤佳.中医药联合标准化特异性免疫治疗儿童支气管哮喘50例临床观察[J].中国中西医结合杂志,2013,33(9):1284-1286.
[9]陈捷,吴敏,曾丽娜.小儿过敏性哮喘的特异性免疫治疗[J].中国现代医生,2013,51(18):29-30.
[10]韦欢,欧维琳,朱春江,等.舌下特异性免疫治疗前后哮喘患儿过敏原及血清总IgE的变化[J].中国医药导报,2012,9(24):8-10.
[11]孙立英,郭胤仕,王怡玮,等.舌下特异性免疫治疗对过敏性哮喘的临床疗效分析[J].临床肺科杂志,2011,16(6):852-853.
[12]郝冀,李晓辕,刘红梅,等.舌下含服尘螨滴剂治疗老年过敏性哮喘患者53例[J].中国老年学杂志,2012,32(14):3066-3067.
[13]曹开梅.小儿过敏性哮喘的特异性免疫治疗[J].中国卫生标准管理,2015,6(19):23-24.
[14]李羚,惠郁,钱俊,等.螨过敏性哮喘患儿标准化特异性免疫治疗3年的有效性观察[J].中国当代儿科杂志,2013,15(5):368-371.
[15]严飞飞,何晓娜,贾圆圆.小青龙方加减联合特异性免疫治疗小儿过敏性哮喘的疗效及其对肺功能的影响[J].亚太传统医药,2018,14(3):181-182.